Goldman Sachs Asset Management

am.gs.com/en-us/advisors/products/life-sciences

VCMatch tracks Goldman Sachs Asset Management as an investor focused on Biotech and Pharma companies, Series B and Series C rounds, and Global, United States, and Europe markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Series B, Series C, Growth

Focus Areas

Biotech, Pharma

Geography

Global, United States, and Europe

Investment Thesis

Goldman Sachs Asset Management’s Life Sciences strategy focuses on investing in innovative companies developing novel medicines that are entering or in earlier stages of clinical development, while deliberately investing at a later stage than traditional life sciences venture funds to “mitigate scientific risk while retaining the significant value creation associated with clinical translation.” They emphasize keeping promising companies private longer to avoid premature public listings and to “better align investment capital with company innovation,” partnering with management teams to accelerate value creation through business and financial strategy, hiring, governance, execution and exits.

Is Goldman Sachs Asset Management right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Goldman Sachs Asset Management is most relevant for founders raising Series B, Series C, and Growth rounds in Biotech and Pharma, especially across Global, United States, and Europe.

Focus statement

The firm targets later-stage life sciences companies developing novel medicines (precision medicine, genetic medicine, immunotherapy and scalable platforms), and also looks for opportunities created by market dislocations and "global innovation" outside the U.S.

Value Add

Multi-channel sourcing powered by Goldman Sachs’ breadth: "We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives."
Later-stage life sciences focus relative to traditional VCs to reduce scientific risk while preserving clinical translation upside: "By investing at a later-stage than traditional life sciences venture funds, WSLS I seeks to mitigate scientific risk while retaining the significant value creation associated with clinical translation."
Active partnership model: they "partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, hire the right management team and board, execute, and achieve strong exits."
Access to Goldman Sachs’ global network and client relationships for sourcing, advisory and exit pathways (positioned as the primary investing area within Goldman Sachs Asset Management).
Broad thematic coverage including precision medicine, genetic medicine, immunotherapy, scalable platforms, market dislocations and non-U.S. innovation, allowing both thematic and opportunistic investments.